Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.74 |
| ▸ | ACACB | O00763 | 1/20 | 0.71 |
| ▸ | ACACA | Q13085 | 1/20 | 0.71 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | CPT2 | P23786 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 5/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4190226 | 1.00 | ACLY (0.74) | ACLYACACBACACATBXAS1TDP1 | |
| SCHEMBL6254902 | 1.00 | ACLY (0.74) | ACLYACACBACACATBXAS1TDP1 | |
| SCHEMBL20474799 | 1.00 | ACLY (0.74) | ACLYACACBACACATBXAS1TDP1 | |
| SCHEMBL1832600 | 1.00 | ACLY (0.74) | ACLYACACBACACATBXAS1TDP1 | |
| SCHEMBL5528331 | 1.00 | ACLY (0.74) | ACLYACACBACACATBXAS1TDP1 | |
| SCHEMBL9177458 | 1.00 | ACLY (0.74) | ACLYACACBACACATBXAS1TDP1 | |
| SCHEMBL5524671 | 1.00 | ACLY (0.74) | ACLYACACBACACATBXAS1TDP1 | |
| Ammonia Solution, Strong SCHEMBL9181436 | 0.97 | ACLY (0.71) | ACLYACACBACACATBXAS1TDP1 | |
| SCHEMBL7222208 | 0.97 | ACLY (0.70) | ACLYACACBACACATBXAS1TDP1 | |
| Ammonia Solution, Strong SCHEMBL9177435 | 0.94 | ACLY (0.67) | ACLYACACBACACATBXAS1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3463330-B1 | DIABETES TREATMENT REGIMENS USING ALPHA, ALPHA-SUBSTITUTED LONG-CHAIN AMPHIPATHIC CARBOXYLATES | SYNDROMEX LTD (IL) | 2022-05-04 | — | — | EP | claimed |
| US-11207285-B2 | Diabetes treatment regimens using alpha, alpha-substituted long-chain amphipathic carboxylates | SYNDROMEX LTD. (IL) | 2021-12-28 | — | — | US | claimed |
| US-20200375933-A1 | DIABETES TREATMENT REGIMENS USING ALPHA, ALPHA-SUBSTITUTED LONG-CHAIN AMPHIPATHIC CARBOXYLATES | SYNDROMEX LTD. (IL) | 2020-12-03 | — | — | US | claimed |
| US-10512624-B2 | Long-chain amphipathic dicarboxylic acids for treatment of diabetes type-1 | SYNDROMEX LTD. (IL) | 2019-12-24 | — | — | US | claimed |
| US-20180235918-A1 | Long-Chain Amphipathic Dicarboxylic Acids for Treatment of Diabetes Type-1 | SYNDROMEX LTD. (IL) | 2018-08-23 | — | — | US | claimed |
| EP-2112134-B1 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | SYNDROMEX LTD (IL) | 2013-10-30 | — | — | EP | claimed |
| EP-1001755-B1 | CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SYNDROME X LTD (IL) | 2011-05-11 | — | — | EP | claimed |
| EP-2112134-A1 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | Syndromex Ltd. (IL) | 2009-10-28 | — | — | EP | claimed |
| US-20040171585-A1 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | BAR-TANA JACOB (IL) | 2004-09-02 | — | — | US | claimed |
| US-20040171688-A1 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | BAR-TANA JACOB (IL) | 2004-09-02 | — | — | US | claimed |
| US-20020037876-A1 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | YISSUM RESEARCH DEVELOPMENT COMPANY OF HEBREW UNIVERSITY OF JERUSALEM | 2002-03-28 | — | — | US | claimed |
| EP-0988274-A4 | CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RES DEV CO (IL) | 2000-10-18 | — | — | EP | claimed |
| EP-0988274-A1 | CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2000-03-29 | — | — | EP | claimed |
| WO-1998030530-A1 | CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RESEARCH DEVELOPMENT CO. OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1998-07-16 | — | — | WO | claimed |
| EP-3463330-B1 | DIABETES TREATMENT REGIMENS USING ALPHA, ALPHA-SUBSTITUTED LONG-CHAIN AMPHIPATHIC CARBOXYLATES | SYNDROMEX LTD (IL) | 2022-05-04 | — | — | EP | disclosed |
| US-11207285-B2 | Diabetes treatment regimens using alpha, alpha-substituted long-chain amphipathic carboxylates | SYNDROMEX LTD. (IL) | 2021-12-28 | — | — | US | disclosed |
| US-20200375933-A1 | DIABETES TREATMENT REGIMENS USING ALPHA, ALPHA-SUBSTITUTED LONG-CHAIN AMPHIPATHIC CARBOXYLATES | SYNDROMEX LTD. (IL) | 2020-12-03 | — | — | US | disclosed |
| EP-0988274-A4 | CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RES DEV CO (IL) | 2000-10-18 | — | — | EP | disclosed |
| EP-0988274-A1 | CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2000-03-29 | — | — | EP | disclosed |
| WO-1998030530-A1 | CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RESEARCH DEVELOPMENT CO. OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1998-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10512624-B2 | Long-chain amphipathic dicarboxylic acids for treatment of diabetes type-1 | IAPP, SLC27A1, SLC16A1 | ACLY 48/4885ACACB 113/4885ACACA 28/4885 |
| US-20180235918-A1 | Long-Chain Amphipathic Dicarboxylic Acids for Treatment of Diabetes Type-1 | IAPP, SLC27A1, SLC16A1 | ACLY 48/4885ACACB 113/4885ACACA 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.